NOTICE: Labnodes now supports email addresses. If your email changed, please update your profile today.

Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 214

Publication Record


Exercise and CKD: Skeletal Muscle Dysfunction and Practical Application of Exercise to Prevent and Treat Physical Impairments in CKD.
Roshanravan B, Gamboa J, Wilund K
(2017) Am J Kidney Dis 69: 837-852
MeSH Terms: Aged, Exercise, Exercise Therapy, Frail Elderly, Hand Strength, Humans, Kidney Failure, Chronic, Male, Mobility Limitation, Muscle Weakness, Muscle, Skeletal, Physical Endurance, Renal Insufficiency, Chronic, Sarcopenia, Walk Test
Show Abstract · Added April 26, 2017
Patients with chronic kidney disease experience substantial loss of muscle mass, weakness, and poor physical performance. As kidney disease progresses, skeletal muscle dysfunction forms a common pathway for mobility limitation, loss of functional independence, and vulnerability to disease complications. Screening for those at high risk for mobility disability by self-reported and objective measures of function is an essential first step in developing an interdisciplinary approach to treatment that includes rehabilitative therapies and counseling on physical activity. Exercise has beneficial effects on systemic inflammation, muscle, and physical performance in chronic kidney disease. Kidney health providers need to identify patient and care delivery barriers to exercise in order to effectively counsel patients on physical activity. A thorough medical evaluation and assessment of baseline function using self-reported and objective function assessment is essential to guide an effective individualized exercise prescription to prevent function decline in persons with kidney disease. This review focuses on the impact of kidney disease on skeletal muscle dysfunction in the context of the disablement process and reviews screening and treatment strategies that kidney health professionals can use in clinical practice to prevent functional decline and disability.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
15 MeSH Terms
Association of Vitamin D Metabolites With Arterial Function in the Hemodialysis Fistula Maturation Study.
van Ballegooijen AJ, Zelnick L, Hoofnagle AN, Hamburg NM, Robinson-Cohen C, Roy-Chaudhury P, Cheung AK, Shiu YT, de Boer IH, Himmelfarb J, Beck G, Imrey PB, Kusek JW, Kestenbaum B, Hemodialysis Fistula Maturation (HFM) Study Group
(2017) Am J Kidney Dis 69: 805-814
MeSH Terms: 25-Hydroxyvitamin D 2, Adult, Aged, Anastomosis, Surgical, Arteries, Brachial Artery, Calcifediol, Carotid Arteries, Chromatography, Liquid, Cohort Studies, Cross-Sectional Studies, Ergocalciferols, Female, Femoral Artery, Humans, Kidney Failure, Chronic, Male, Middle Aged, Nitroglycerin, Prospective Studies, Pulse Wave Analysis, Radial Artery, Renal Dialysis, Tandem Mass Spectrometry, Vascular Stiffness, Vasodilation, Vasodilator Agents, Veins, Vitamin D
Show Abstract · Added September 19, 2017
BACKGROUND - Disturbances in vitamin D metabolism are common in patients with end-stage renal disease and may contribute to vascular dysfunction.
STUDY DESIGN - Cross-sectional.
SETTING & PARTICIPANTS - We evaluated 558 of 602 participants at baseline of the Hemodialysis Fistula Maturation (HFM) Study, a 7-center prospective cohort study of a cohort of patients with chronic kidney disease awaiting arteriovenous fistula (AVF) creation surgery.
FACTOR - 4 vitamin D metabolites measured with liquid chromatography-tandem mass spectroscopy from samples obtained within 4 weeks prior to AVF surgery.
OUTCOMES - Vasodilator functions and measurements of arterial stiffness.
MEASUREMENTS - Trained HFM Study personnel measured brachial artery flow-mediated dilation, nitroglycerin-mediated dilation, and carotid-femoral and carotid-radial pulse wave velocities (PWVs) prior to AVF creation. We evaluated associations after basic adjustment for sex, age, and clinical site and more fully adjusted additionally for baseline education, smoking, body mass index, diabetes, dialysis status, and medication use.
RESULTS - Mean participant age was 55±13 (SD) years and 65% were receiving maintenance dialysis. None of the vitamin D metabolites were significantly associated with flow-mediated dilation, carotid-femoral PWV, or carotid-radial PWV in basic or fully adjusted analyses. Higher serum concentrations of bioavailable vitamin D and 1,25-dihydroxyvitamin D were associated with 0.62% and 0.58% greater nitroglycerin-mediated dilation values, respectively, in basic models; however, these associations were no longer statistically significant with full adjustment. There were no significant associations of vitamin D metabolites with carotid-femoral or carotid-radial PWV in fully adjusted analyses.
LIMITATIONS - Cross-sectional ascertainment of vitamin D metabolites and vascular functions late during the course of kidney disease.
CONCLUSIONS - Serum concentrations of vitamin D metabolites are not associated with vasodilator functions or vascular stiffness at baseline in a cohort study of patients with chronic kidney disease awaiting AVF creation surgery. Laboratory measurements of vitamin D metabolites are unlikely to provide useful information regarding vascular functions in this setting.
Copyright © 2017 National Kidney Foundation, Inc. All rights reserved.
0 Communities
1 Members
0 Resources
29 MeSH Terms
Effect of Coenzyme Qon Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQBiomarker Trial.
Rivara MB, Yeung CK, Robinson-Cohen C, Phillips BR, Ruzinski J, Rock D, Linke L, Shen DD, Ikizler TA, Himmelfarb J
(2017) Am J Kidney Dis 69: 389-399
MeSH Terms: Biomarkers, Double-Blind Method, Female, Heart, Humans, Kidney Failure, Chronic, Male, Middle Aged, Oxidative Stress, Pilot Projects, Renal Dialysis, Ubiquinone
Show Abstract · Added September 19, 2017
BACKGROUND - Oxidative stress is highly prevalent in patients with end-stage renal disease and is linked to excess cardiovascular risk. Identifying therapies that reduce oxidative stress has the potential to improve cardiovascular outcomes in patients undergoing maintenance dialysis.
STUDY DESIGN - Placebo-controlled, 3-arm, double-blind, randomized, clinical trial.
SETTING & PARTICIPANTS - 65 patients undergoing thrice-weekly maintenance hemodialysis.
INTERVENTION - Patients were randomly assigned in a 1:1:1 ratio to receive once-daily coenzyme Q(CoQ; 600 or 1,200mg) or matching placebo for 4 months.
OUTCOMES - The primary outcome was plasma oxidative stress, defined as plasma concentration of F-isoprotanes. Secondary outcomes included levels of plasma isofurans, levels of cardiac biomarkers, predialysis blood pressure, and safety/tolerability.
MEASUREMENTS - F-isoprostanes and isofurans were measured as plasma markers of oxidative stress, and N-terminal pro-brain natriuretic peptide and troponin T were measured as cardiac biomarkers at baseline and 1, 2, and 4 months.
RESULTS - Of 80 randomly assigned patients, 15 were excluded due to not completing at least 1 postbaseline study visit and 65 were included in the primary intention-to-treat analysis. No treatment-related major adverse events occurred. Daily treatment with 1,200mg, but not 600mg, of CoQsignificantly reduced plasma F-isoprostanes concentrations at 4 months compared to placebo (adjusted mean changes of -10.7 [95% CI, -7.1 to -14.3] pg/mL [P<0.001] and -8.3 [95% CI, -5.5 to -11.0] pg/mL [P=0.1], respectively). There were no significant effects of CoQtreatment on levels of plasma isofurans, cardiac biomarkers, or predialysis blood pressures.
LIMITATIONS - Study not powered to detect small treatment effects; difference in baseline characteristics among randomized groups.
CONCLUSIONS - In patients undergoing maintenance hemodialysis, daily supplementation with 1,200mg of CoQis safe and results in a reduction in plasma concentrations of F-isoprostanes, a marker of oxidative stress. Future studies are needed to determine whether CoQsupplementation improves clinical outcomes for patients undergoing maintenance hemodialysis.
Copyright © 2016. Published by Elsevier Inc.
0 Communities
1 Members
0 Resources
12 MeSH Terms
CKD and Muscle Mitochondrial Energetics.
Roshanravan B, Kestenbaum B, Gamboa J, Jubrias SA, Ayers E, Curtin L, Himmelfarb J, de Boer IH, Conley KE
(2016) Am J Kidney Dis 68: 658-659
MeSH Terms: Adenosine Triphosphate, Adult, Aged, Case-Control Studies, Energy Metabolism, Female, Humans, Magnetic Resonance Spectroscopy, Male, Middle Aged, Mitochondria, Muscle, Muscle, Skeletal, Optical Imaging, Oxygen Consumption, Renal Insufficiency, Chronic, Spectrum Analysis
Added October 28, 2016
0 Communities
1 Members
0 Resources
16 MeSH Terms
Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS).
Young BA, Katz R, Boulware LE, Kestenbaum B, de Boer IH, Wang W, Fülöp T, Bansal N, Robinson-Cohen C, Griswold M, Powe NR, Himmelfarb J, Correa A
(2016) Am J Kidney Dis 68: 229-239
MeSH Terms: African Americans, Female, Humans, Kidney, Kidney Function Tests, Male, Middle Aged, Prospective Studies, Renal Insufficiency, Risk Factors, Time Factors
Show Abstract · Added September 19, 2017
BACKGROUND - Racial differences in rapid kidney function decline exist, but less is known regarding factors associated with rapid decline among African Americans. Greater understanding of potentially modifiable risk factors for early kidney function loss may help reduce the burden of kidney failure in this high-risk population.
STUDY DESIGN - Prospective cohort study.
SETTING & PARTICIPANTS - 3,653 African American participants enrolled in the Jackson Heart Study (JHS) with kidney function data from 2 of 3 examinations (2000-2004 and 2009-2013). Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine using the CKD-EPI creatinine equation.
PREDICTORS - Demographics, socioeconomic status, lifestyle, and clinical risk factors for kidney failure.
OUTCOMES - Rapid decline was defined as a ≥30% decline in eGFR during follow-up. We quantified the association of risk factors with rapid decline in multivariable models.
MEASUREMENTS - Clinical (systolic blood pressure and albuminuria [albumin-creatinine ratio]) and modifiable risk factors.
RESULTS - Mean age was 54±12 (SD) years, 37% were men, average body mass index was 31.8±7.1kg/m(2), 19% had diabetes mellitus (DM), and mean eGFR was 96.0±20mL/min/1.73m(2) with an annual rate of decline of 1.27mL/min/1.73m(2). Those with rapid decline (11.5%) were older, were more likely to be of low/middle income, and had higher systolic blood pressures and greater DM than those with nonrapid decline. Factors associated with ≥30% decline were older age (adjusted OR per 10 years older, 1.51; 95% CI, 1.34-1.71), cardiovascular disease (adjusted OR, 1.53; 95% CI, 1.12-2.10), higher systolic blood pressure (adjusted OR per 17mmHg greater, 1.22; 95% CI, 1.06-1.41), DM (adjusted OR, 2.63; 95% CI, 2.02-3.41), smoking (adjusted OR, 1.60; 95% CI, 1.10-2.31), and albumin-creatinine ratio > 30mg/g (adjusted OR, 1.55; 95% CI, 1.08-1.21). Conversely, results did not support associations of waist circumference, C-reactive protein level, and physical activity with rapid decline.
LIMITATIONS - No midstudy creatinine measurement at examination 2 (2005-2008).
CONCLUSIONS - Rapid decline heterogeneity exists among African Americans in JHS. Interventions targeting potentially modifiable factors may help reduce the incidence of kidney failure.
Published by Elsevier Inc.
0 Communities
1 Members
0 Resources
11 MeSH Terms
Galectin-3 and Soluble ST2 and Kidney Function Decline in Older Adults: The Cardiovascular Health Study (CHS).
Bansal N, Katz R, Seliger S, DeFilippi C, Sarnak MJ, Delaney JA, Christenson R, de Boer IH, Kestenbaum B, Robinson-Cohen C, Ix JH, Shlipak MG
(2016) Am J Kidney Dis 67: 994-6
MeSH Terms: Aged, Cohort Studies, Creatinine, Cystatin C, Female, Galectin 3, Glomerular Filtration Rate, Humans, Interleukin-1 Receptor-Like 1 Protein, Logistic Models, Longitudinal Studies, Male, Prognosis, Renal Insufficiency, Chronic
Added September 19, 2017
0 Communities
1 Members
0 Resources
14 MeSH Terms
An Informed and Activated Patient: Addressing Barriers in the Pathway From Education to Outcomes.
Wright Nunes JA, Cavanaugh KL, Fagerlin A
(2016) Am J Kidney Dis 67: 1-4
MeSH Terms: Anticholesteremic Agents, Educational Status, Ezetimibe, Female, Humans, Male, Renal Insufficiency, Chronic, Simvastatin
Added January 4, 2016
0 Communities
1 Members
0 Resources
8 MeSH Terms
Acute Kidney Injury Incidence in Noncritically Ill Hospitalized Children, Adolescents, and Young Adults: A Retrospective Observational Study.
McGregor TL, Jones DP, Wang L, Danciu I, Bridges BC, Fleming GM, Shirey-Rice J, Chen L, Byrne DW, Van Driest SL
(2016) Am J Kidney Dis 67: 384-90
MeSH Terms: Acute Kidney Injury, Adolescent, Child, Child, Preschool, Cohort Studies, Creatinine, Female, Hospital Mortality, Humans, Incidence, Infant, Inpatients, Kidney Function Tests, Length of Stay, Male, Retrospective Studies, Risk Factors, Severity of Illness Index, Tertiary Care Centers, Time Factors, United States, Young Adult
Show Abstract · Added April 11, 2017
BACKGROUND - Acute kidney injury (AKI) has been characterized in high-risk pediatric hospital inpatients, in whom AKI is frequent and associated with increased mortality, morbidity, and length of stay. The incidence of AKI among patients not requiring intensive care is unknown.
STUDY DESIGN - Retrospective cohort study.
SETTING & PARTICIPANTS - 13,914 noncritical admissions during 2011 and 2012 at our tertiary referral pediatric hospital were evaluated. Patients younger than 28 days or older than 21 years of age or with chronic kidney disease (CKD) were excluded. Admissions with 2 or more serum creatinine measurements were evaluated.
FACTORS - Demographic features, laboratory measurements, medication exposures, and length of stay.
OUTCOME - AKI defined as increased serum creatinine level in accordance with KDIGO (Kidney Disease: Improving Global Outcomes) criteria. Based on time of admission, time interval requirements were met in 97% of cases, but KDIGO time window criteria were not strictly enforced to allow implementation using clinically obtained data.
RESULTS - 2 or more creatinine measurements (one baseline before or during admission and a second during admission) in 2,374 of 13,914 (17%) patients allowed for AKI evaluation. A serum creatinine difference ≥0.3mg/dL or ≥1.5 times baseline was seen in 722 of 2,374 (30%) patients. A minimum of 5% of all noncritical inpatients without CKD in pediatric wards have an episode of AKI during routine hospital admission.
LIMITATIONS - Urine output, glomerular filtration rate, and time interval criteria for AKI were not applied secondary to study design and available data. The evaluated cohort was restricted to patients with 2 or more clinically obtained serum creatinine measurements, and baseline creatinine level may have been measured after the AKI episode.
CONCLUSIONS - AKI occurs in at least 5% of all noncritically ill hospitalized children, adolescents, and young adults without known CKD. Physicians should increase their awareness of AKI and improve surveillance strategies with serum creatinine measurements in this population so that exacerbating factors such as nephrotoxic medication exposures may be modified as indicated.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
22 MeSH Terms
Quality training, quality board examinations, quality nephrologists.
Berns JS, Ikizler TA
(2015) Am J Kidney Dis 66: 7-8
MeSH Terms: Educational Measurement, Humans, Nephrology, Quality Assurance, Health Care, Specialty Boards
Added August 5, 2015
0 Communities
1 Members
0 Resources
5 MeSH Terms
Peer kidney care initiative 2014 report: dialysis care and outcomes in the United States.
Weinhandl E, Constantini E, Everson S, Gilbertson D, Li S, Solid C, Anger M, Bhat JG, DeOreo P, Krishnan M, Nissenson A, Johnson D, Ikizler TA, Maddux F, Sadler J, Tyshler L, Parker T, Schiller B, Smith B, Lindenfeld S, Collins AJ
(2015) Am J Kidney Dis 65: Svi, S1-140
MeSH Terms: Catheterization, Central Venous, Health Status Disparities, Hospitalization, Humans, Infection, Kidney Failure, Chronic, Mortality, Outcome Assessment (Health Care), Quality Improvement, Renal Dialysis, United States
Added August 5, 2015
0 Communities
1 Members
0 Resources
11 MeSH Terms